Anti-Mouse Osteopontin [Clone 100D3] - Purified in vivo PLATINUM™ Functional Grade - 25 mg

Primary Monoclonal Antibodies

2 - 8 °C Wet Ice

Osteopontin is a phosphorylated glycoprotein1 that regulates bone formation, bone tissue remodeling, and promotes osteogenic differentiation of mesenchymal stem cells2. Osteopontin also inhibits adipogenic differentiation, can induce angiogenesis, and promotes leukocyte
adhesion. Osteopontin performs its regulatory roles by interacting with integrins to activate
downstream signaling pathways. In cancer, increased levels of osteopontin are associated with
migration, invasion, and poor prognosis. Osteopontin promotes tumor development by activating
the PI3K/pAkt/NF-κB pathway when interacting with the αvβ3 integrin and can promote cancer
invasion when interacting with CD44. Osteopontin is thus a target for the development of cancer
treatments, including transcription and translation inhibitors as well as blockade by
immunotherapy.

100D3 was generated by immunizing C57BL/6 mice with recombinant osteopontin protein1.
Mice with the highest osteopontin antibody titer, as determined by ELISA, were selected for
spleen cell electro-fusion with SP2/0 myeloma cells. Fused cells were screen by ELISA with
osteopontin protein and then by T cell proliferation rescue assay in anti-CD3/CD28/osteopontin-
coated plates.

100D3 is a neutralizing antibody that inhibits colonic tumor growth in vivo and increases tumor-
specific cytotoxic T lymphocyte effector function1.

≥ 5.0 mg/ml

Osteopontin is a secreted protein found in bone that is also expressedintracellularly in other tissues, including cardiac fibroblasts, dendritic cells, macrophages, smooth muscle, endothelial cells, kidney, and brain. In cancer, osteopontin can also be expressedin tumor cells, myeloid cells, and innate lymphoid cells. Additionally, osteopontin is elevated inhuman cancer patient peripheral blood.